Efficacy and Safety of Rejuviel V in the Correction of Midface Volume Deficit

NAActive, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 7, 2024

Primary Completion Date

March 8, 2026

Study Completion Date

March 30, 2026

Conditions

Mid-face Volume Deficit

Interventions

DEVICE

Rejuviel V® with lidocaine

Crosslinked hyaluronic acid (HA) 22 mg/mL + 0.3% lidocaine hydrochloride.

DEVICE

JUVEDERM® VOLUMA® with lidocaine

Crosslinked hyaluronic acid (HA) 20 mg/mL + 0.3% lidocaine hydrochloride.

Trial Locations (1)

Chung-Ang University Hospital, Soeul